STORM Therapeutics

Description

STORM Therapeutics develops small molecule inhibitors of RNA-modifying enzymes, including STC-15, a METTL3 inhibitor in clinical evaluation, to treat cancer and select sarcomas through RNA epigenetics and RNA modification.

STORM Therapeutics is located in the Cambridge ecosystem.

Related

• Oy Medix BiochemicaOy Medix Biochemica supplies diagnostic raw materials, including monoclonal and polyclonal antibodies, native and recombinant antigens,…
• AntabioAntabio develops antibacterial therapies for multidrug-resistant Gram-negative infections and advances Meropenem-Pilabactam, a…
• Phlox TherapeuticsPhlox Therapeutics develops precision RNA-based therapies to treat rare genetic cardiomyopathies, creating therapeutic candidates and…
• CircioCircio develops circular RNA and immunotherapy medicines, including circVec AAV gene therapy work that uses circular RNA to enhance…
• MogrifyMogrify develops platform technologies for direct cellular reprogramming that analyze transcriptomic, gene regulatory, and epigenetic data…
• Pharmasum TherapeuticsPharmasum Therapeutics discovers and develops neurological-disease drugs, including PST-674, a proprietary DYRK1A inhibitor intended to…
• Cyted HealthCyted Health combines minimally invasive cell collection with molecular analysis to build diagnostic tests (EndoSign®) for earlier…
• c-LEctac-LEcta develops and produces enzyme products and integrates enzyme discovery, strain engineering and process development to create…
• EndomagEndomag provides surgical guidance products for breast cancer procedures, including lesion localization and sentinel node biopsy, to help…